| abstract |
Disclosed herein are double-stranded RNA nucleic acid molecules that include at least one pyrazolotriazine nucleotide analog and that have been modified to exhibit one of: increased on-target activity when compared to unmodified or similarly modified dsRNA, Increased target specificity, enhanced nuclease stability, reduced off-target activity and/or reduced immunogenicity; pharmaceutical compositions comprising said molecules and methods of use thereof in therapy. |